Search This Blog

Tuesday, November 3, 2026

Amneal cuts full-year 2026 operating cash flow guidance by $25M

 

Amneal Pharmaceuticals beats Q3 2026 estimates, raises 2026 revenue, EBITDA, EPS guidance but cuts full-year 2026 operating cash flow guidance by $25M

  • Q3 non-GAAP EPS $0.26 (+53% YoY) on revenue $862.7M (+10% YoY), both beating estimates.
  • Company disclosed higher leverage, highlighting growing concerns over cash generation and the balance sheet.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)